843663-66-1 | Bedaquiline

Availability
Typically In Stock

Description

• Catalog Number: AB50669
• Chemical Name: Bedaquiline
• CAS Number: 843663-66-1
• Molecular Formula: C32H31BrN2O2
• Molecular Weight: 555.5047
• MDL Number: MFCD22628872
• SMILES: COc1nc2ccc(cc2cc1[C@H]([C@](c1cccc2c1cccc2)(CCN(C)C)O)c1ccccc1)Br

Computed Properties

• Complexity: 715
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 8
• XLogP3: 7.2

Literature

• Supramolecular strategy for reducing the cardiotoxicity of bedaquiline without compromising its antimycobacterial efficacy.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180901

• Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.

  Antimicrobial agents and chemotherapy 20140101

• Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents.

  Bioorganic & medicinal chemistry letters 20131115

• Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.

  Journal of medicinal chemistry 20130523

• 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

  Lancet (London, England) 20120915

• Tuberculosis: the drug development pipeline at a glance.

  European journal of medicinal chemistry 20120501

• Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.

  Journal of medicinal chemistry 20120426

• Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.

  PloS one 20120101

• Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.

  American journal of respiratory and critical care medicine 20110915

• The TB Alliance: overcoming challenges to chart the future course of TB drug development.

  Future medicinal chemistry 20110801

• Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives.

  European journal of medicinal chemistry 20110401

• Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

  PloS one 20110101

• Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.

  PloS one 20110101

• [Present and future in the use of anti-tubercular drugs].

  Pneumologia (Bucharest, Romania) 20110101

• Drugs in development for tuberculosis.

  Drugs 20101203

• Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20101201

• Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

  Tuberculosis (Edinburgh, Scotland) 20100901

• [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].

  Medecine et maladies infectieuses 20100701

• In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

  Antimicrobial agents and chemotherapy 20100701

• Current development and future prospects in chemotherapy of tuberculosis.

  Respirology (Carlton, Vic.) 20100701

• TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

  Future microbiology 20100601

• Update in tuberculosis 2009.

  American journal of respiratory and critical care medicine 20100315

• Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

  American journal of respiratory and critical care medicine 20090915

• Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry 20090401

• A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

  American journal of respiratory and critical care medicine 20090101

• Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility.

  American journal of respiratory and critical care medicine 20090101

• [Some new antitubercular agents].

  Revue medicale suisse 20080319

• New anti-tuberculosis drugs with novel mechanisms of action.

  Current medicinal chemistry 20080101

• In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.

  Antimicrobial agents and chemotherapy 20071101

• New tuberculosis therapeutics: a growing pipeline.

  The Journal of infectious diseases 20070815

• A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.

  Proteins 20070601

• New drugs being developed for the treatment of tuberculosis.

  Expert opinion on investigational drugs 20050701

• New small-molecule synthetic antimycobacterials.

  Antimicrobial agents and chemotherapy 20050601

• A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

  Science (New York, N.Y.) 20050114

• Microbiology. TB--a new target, a new drug.

  Science (New York, N.Y.) 20050114

• Medicine. New TB drug promises shorter, simpler treatment.

  Science (New York, N.Y.) 20041210